Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (232 records) with 2024 (225) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,224 records in scope (CR5), not by the ranked leaders only.
Circulating tumor DNA (ctDNA) sample handling spans the physical and procedural steps between a blood draw and a sequencing-ready library: plasma separation protocols, genomic DNA contamination control, input volume standardisation, extraction yield optimisation, fragment size distribution analysis, and storage stability. This dataset covers 2,224 patent families published between 2015 and mid-2026 that combine cfDNA or ctDNA subject matter with at least one of these handling-specific technical elements. It is a narrower, more operational slice of the broader liquid biopsy field — closer to the wet-lab and QC layer than to the diagnostic algorithms built on top of it.
Because the search pairs a biological target (ctDNA, cfDNA, plasma cfDNA) with a handling-specific term, the corpus skews toward assignees who patent process and platform claims — sequencing and diagnostics companies, alongside university labs that originated core separation and stabilisation methods. Publication naturally lags filing by around 18 months, so the last one to two years in any trend chart will look thinner than the underlying filing activity actually was.
Two views of the same 2,224-record corpus: how filing volume has moved year over year, and how the subject matter splits across IPC subclasses.
Filings peaked in 2018 at 303 records and have since settled into a lower, steadier band; 2021 (232) to 2024 (225) — the last year that can be read as complete — is essentially flat at -3%. Earlier and later years either predate the field's initial filing wave or are still filling in behind the publication lag, so treat the most recent one to two years as undercounted rather than as evidence of decline.
C12Q (enzyme/DNA measuring and testing) appears on 74.5% of all records, confirming that most filings anchor on the molecular assay itself. G16B bioinformatics (32.1%) and G16H healthcare informatics (12.8%) show a large minority of filings also stake claims on the data-processing layer that consumes the handled sample, while G01N material analysis (12.0%) and A61K medicinal preparations (9.4%) mark smaller but active adjacent claim territory. Because records can carry multiple IPC codes, these shares are each measured against the full 2,224-record base and will not sum to 100%.
Shares are the percentage of the 2,224 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about circulating tumor dna sample handling and every answer comes back with the patent numbers behind it.
Try EurekaThe disclosure describes preparing ctDNA reference samples by inducing apoptosis in tumor cells to generate DNA fragments, then extracting DNA from those cells to produce reference material. The method is designed to be simple, applicable across various tumor cell lines, and to retain variant information so it can simulate ctDNA behaviour in animal models, with the resulting reference samples intended to support assay calibration and evaluation.Filed by SEEKIN INC., published 2023-03-16.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2016130704A2 | Methods and compositions for analyzing cellular components | 285 |
| 2 | WO2016015058A2 | Methods of determining tissues and/or cell types giving rise to cell-free DNA, and methods of identifying a d… | 207 |
| 3 | WO2015164432A1 | Detecting mutations and ploidy in chromosomal segments | 196 |
| 4 | US20170211143A1 | Methods of determining tissues and/or cell types giving rise to cell-free DNA, and methods of identifying a d… | 190 |
| 5 | US20170107576A1 | Detecting mutations and ploidy in chromosomal segments | 162 |
| 6 | US20150147815A1 | Cell free DNA diagnostic testing standards | 161 |
| 7 | US20160369333A1 | Methods for simultaneous amplification of target loci | 136 |
| 8 | US10316362B2 | Methods for simultaneous amplification of target loci | 128 |
| 9 | US10557172B2 | Methods for simultaneous amplification of target loci | 127 |
| 10 | US10538814B2 | Methods for simultaneous amplification of target loci | 125 |
Citation counts are drawn from within this searched corpus and favour older filings that have had more time to accumulate citations — read them as a signal of influence on the field, not as a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading concentration, technology mix and citation patterns together points to where claim space is already dense and where it remains open.
Just five assignees account for 692 of the 2,224 records in scope, with the leader alone holding 193. New entrants filing core extraction or contamination-control claims should expect to run into this group's prior art first.
225 records in 2024 against 232 in 2021 reads as stability rather than a downturn, especially once the 18-month publication lag on the newest years is taken into account.
Three in four records touch core enzyme/DNA measurement (C12Q), but nearly a third also carry a bioinformatics classification (G16B). Sample-handling patents are increasingly bundled with the downstream analytics that use the sample.
The strongest co-assignee link in this corpus ties an academic hospital consortium to a sequencing-diagnostics company, a pattern consistent with core IP originating in university labs and being commercialised through sequencing partners.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to circulating tumor dna sample handling, with the prior art for and against each one.
Filing is concentrated among a small set of sequencing, diagnostics and academic assignees, but the momentum data suggests that even leaders are filing less each year, and several specific technical branches remain lightly claimed.
The top-ranked assignee's 193 records put it well ahead of the field, though its most recent-year momentum shows a sharp drop, consistent with a maturing rather than expanding filing programme.
The gap from fifth place (81 records) to tenth (58) is narrower than the gap from first to fifth, indicating a genuine second tier of active filers rather than a single dominant player and a long tail.
Several of the most active historical assignees show sharp year-over-year declines in their latest reported year, with some down to zero new filings. This is consistent with the publication lag understating true recent activity, but it also signals that the earliest movers may be shifting effort elsewhere.
| Assignee | Recent year | YoY |
|---|---|---|
| Johns Hopkins University | 4 | -67% |
| Natera Inc | 3 | -81% |
| Illumina Inc | 1 | -67% |
| Grail Inc | 0 | -100% |
| NIPD Genetics Ltd | 0 | — |
| Verinata Health Inc | 0 | — |
| The Chinese University of Hong Kong | 0 | -100% |
| TEMPUS LABS INC | 0 | — |
The dataset points to a field where core assay claims are dense but several handling-specific sub-areas remain open. The next step is usually to test a specific claim idea against this same corpus.
Run a candidate claim on fragment-size QC, low-input extraction, or storage stability against the full corpus to see how crowded that specific branch actually is before drafting.
Explore in Patsnap EurekaSet up ongoing monitoring of the leading assignees' filing behaviour, since several show sharp recent-year pullbacks that may signal a shift in strategy worth watching closely.
Explore in Patsnap EurekaOne assignee leads the ranked field with 193 records, well ahead of the fifth-place assignee at 81 and the tenth-place assignee at 58. The top five assignees combined hold 692 records, or 31.1% of all 2,224 records in scope, so filing influence is concentrated but not held by a single company. The ranking covers 100 companies in total, and most of them hold far fewer records than the leaders, forming a long tail below the top ten.
Filing volume peaked in 2018 at 303 records and has since settled into a lower band; comparing 2021 (232 records) to 2024 (225 records), the last year that can be treated as reasonably complete, shows a -3% change, which reads as roughly flat rather than a clear decline. Because publication lags filing by about 18 months, the years closest to the present will always look thinner than they eventually turn out to be. Anyone judging momentum should compare complete years like 2021-2024 rather than reading the last one or two years as a downturn.
C12Q, covering enzyme and DNA measuring and testing, appears on 74.5% of all 2,224 records, making it by far the most common classification in this corpus. Bioinformatics (G16B) shows up on 32.1% of records and healthcare informatics (G16H) on 12.8%, indicating that a large share of sample-handling filings also claim the downstream data-processing methods that consume the handled sample. Because a single record can carry several IPC codes, these percentages are each measured against the full record count and add up to more than 100%.
Relative to the dense coverage of core assay and extraction claims, sub-areas such as fragment size distribution QC automation, double-spin protocol standardisation, low-input-volume extraction yield methods, and long-term storage stability formulations show comparatively thin dedicated coverage in this corpus. That does not mean these areas are unpatented, but that they are less saturated than the core C12Q assay space. A freedom-to-operate search focused specifically on these branches, rather than on ctDNA broadly, is the more productive way to test whether a specific claim idea is open.
US20230079748A1, filed by SEEKIN INC. and published 2023-03-16, is a useful representative filing: it describes inducing apoptosis in tumor cells to generate DNA fragments and then extracting DNA to produce ctDNA reference samples for assay calibration. It illustrates a recurring pattern in this corpus, where sample-preparation methods are patented specifically to support downstream test validation rather than as a diagnostic method in themselves. Reviewing its claim scope alongside the most-cited older filings in this space gives a practical sense of how narrow or broad reference-sample claims tend to be drafted.
Go past this page: query the whole circulating tumor dna sample handling corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page